Open AccessAdvantages of osteoarthritis combined treatment with symptomatic slow-acting drugs
Author(s) -
Е. В. Зонова
Publication year - 2021
Publication title -
sovremennaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-158X
pISSN - 1996-7012
DOI - 10.14412/1996-7012-2021-2-126-131
Subject(s) - osteoarthritis , chondroitin , chondroitin sulphate , medicine , malignancy , glucosamine , phenotype , pharmacology , biology , pathology , gene , glycosaminoglycan , genetics , biochemistry , alternative medicine , anatomy
The effectiveness of combined drugs, consisting of chondroitin and glucosamine (GA) in the treatment of osteoarthritis (OA) is discussed. Due to their high safety and pleiotropic effects, these drugs can be used in patients with OA (primarily with metabolic and inflammatory phenotypes) and comorbid diseases. The effect of oral chondroitin and GA on the intestinal microbiota is described: regulation of the composition, metabolic and immunological activity of intestinal microbiota. The relationship between the regular administration of chondroitin and GA and decrease in overall mortality and mortality from cardiovascular diseases, as well as the decrease of malignancy development risk is marked.